OCTREOSCAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OCTREOSCAN (OCTREOSCAN).
Octreotide acetate, a synthetic octapeptide analog of somatostatin, binds to somatostatin receptors (SSTR2 and SSTR5) on neuroendocrine tumors, inhibiting the secretion of growth hormone, insulin, glucagon, and other peptides. The radiolabeled formulation (In-111 pentetreotide) localizes to these tumors for imaging.
| Metabolism | Primarily hepatic metabolism via peptidases, with minor renal excretion; half-life ~1.5 hours. |
| Excretion | Primarily renal: 50% unchanged drug excreted in urine within 24 hours. Biliary/fecal elimination accounts for approximately 10-20%. |
| Half-life | Terminal elimination half-life is approximately 1.7 hours for the intact peptide and 3.3 hours for the radiometabolite complex. Clinical context: Short half-life necessitates continuous infusion for sustained effect. |
| Protein binding | Approximately 65% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Approximately 0.4 L/kg, indicating distribution mainly into extracellular fluid. Large Vd (e.g., 1 L/kg) would suggest extensive tissue binding. |
| Bioavailability | Not applicable for oral route; administered intravenously only, thus bioavailability is 100%. |
| Onset of Action | Intravenous: Radiopharmaceutical localization occurs within 1 hour post-injection; clinical imaging typically performed at 4 and 24 hours. No therapeutic effect; diagnostic use only. |
| Duration of Action | Diagnostic imaging window: Up to 24 hours post-injection due to tumor localization. No therapeutic duration; radioactivity decays with physical half-life of 6.02 hours (In-111). |
111 MBq (3 mCi) of Indium-111 pentetreotide intravenously over 1 minute, single dose for planar imaging; for SPECT/CT, up to 222 MBq (6 mCi) may be used.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment guidelines available; use caution in severe renal impairment (GFR <30 mL/min) due to delayed clearance and increased radiation exposure. |
| Liver impairment | No specific dose adjustment recommended for Child-Pugh A or B; monitor for adverse effects in Child-Pugh C due to limited data. |
| Pediatric use | Dose based on body surface area: 3-5 mCi (111-185 MBq) adjusted by weight (0.14 mCi/kg, minimum 1 mCi), administered intravenously. |
| Geriatric use | No specific dose adjustment required; consider age-related renal function decline and monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OCTREOSCAN (OCTREOSCAN).
| Breastfeeding | Octreotide is excreted in human milk; M/P ratio not established. Due to potential for suppression of neonatal growth and hypoglycemia, breastfeeding is not recommended during therapy and for 24 hours after administration. |
| Teratogenic Risk | Octreotide, the active component of Octreoscan, crosses the placenta. First trimester: limited human data suggest potential risk for fetal growth restriction and developmental anomalies based on animal studies (skeletal abnormalities at doses 0.5-10 times human exposure). Second trimester: potential for fetal growth restriction, preterm labor. Third trimester: risk of transient neonatal hypoglycemia and hyperbilirubinemia due to somatostatin inhibition of growth hormone and glucagon. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to octreotide or any component of the kit","Concurrent use with cisapride (risk of QT prolongation)"]
| Precautions | ["Risk of cholelithiasis due to inhibition of gallbladder contraction and bile secretion","May cause hypoglycemia or hyperglycemia; monitor blood glucose","Bradycardia and cardiac conduction abnormalities; use caution with antiarrhythmics","Renal impairment may require dose adjustment","Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome) reported","Radiation exposure risk with In-111 pentetreotide"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum glucose, thyroid function, and blood pressure regularly. Fetal ultrasound for growth parameters (serial), amniotic fluid index, and biophysical profile in third trimester. Neonatal monitoring for hypoglycemia, hyperbilirubinemia, and growth parameters after delivery. |
| Fertility Effects | Octreotide may suppress secretion of GH, TSH, and gonadotropins, potentially causing irregular menstrual cycles and reduced fertility in women; in men, decreased libido and spermatogenesis. Effects are reversible upon discontinuation. |